Polymyositis News

Among patients with myositis, younger individuals with dermatomyositis are more likely to experience pain, while those with polymyositis are more likely to receive opioids, according to data published in Rheumatology.

Guiding patients with juvenile dermatomyositis from pediatric to adult care is essential to minimize comorbidities and complications, according to data presented at EULAR 2022 Congress.

Specialized physical therapy may prevent deterioration and improve sexual function in female patients with systemic sclerosis and idiopathic inflammatory myopathies, according to data presented at the EULAR 2022 Congress.

Myositis Awareness Month is focused on raising awareness and amplifying voices for patients with diseases falling under the myositis umbrella.

DESTIN, Fla. — Hydroxychloroquine may no longer be the optimal treatment option for systemic dermatomyositis, according to data presented at the Congress of Clinical Rheumatology East.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.

Nintedanib slows the rate of forced vital capacity decline in patients with fibrosing autoimmune disease-related interstitial lung disease, with adverse events manageable for most, according to data published in Arthritis & Rheumatology.

High anti-cyclic citrullinated peptide levels and pain in the hands or feet indicate an increased risk for progression to inflammatory arthritis, especially rheumatoid arthritis, according to data published in Arthritis Research & Therapy.

One out of three registered randomized controlled trials on connective tissue diseases are never completed or published, representing a “waste of energy or resources” that may skew meta-analyses, according to researchers.

Kristin B. Highland, MD, does it all and makes it look easy. In this episode, we discuss how to follow your dreams, balance your life and define success on your own terms.